Sanofi rolls out new Fluzone shots; Alexion's Soliris driving myasthenia gravis market growth;

> Sanofi's ($SNY) vaccines division shipped its first doses of Fluzone for the 2015-2016 influenza season in the U.S. Release

> Alexion's ($ALXN) rare disease drug Soliris could drive the value of the myasthenia gravis market to $550 million by 2024, GlobalData figures. Report

> Misuse of the anticoagulant warfarin is causing deaths and injuries in nursing homes, a ProPublica investigation found. Report

> Taiwan's pharma market is expected to rise to $8.4 billion by 2020, despite ongoing political tensions with China. Release

> Sarepta Therapeutics ($SRPT) is looking to buy another drug to treat Duchenne muscular dystrophy in its race with BioMarin Pharmaceutical ($BMRN) in the field. Report

And Finally... The FDA warned about the cardiovascular risks of NSAIDs last week, and experts now say they should be used sparingly. Report

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?

Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.